Evidence map›Paper›PMID 28508969›Full record

ArticleCEN case reports2016

Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation.

Ryosuke Usui, Masaki Takahashi, Kosaku Nitta, Minako Koike

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CEN case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Lipoprotein Glomerulopathy, First Case Report from Canada.International journal of nephrology and renovascular disease · 2022
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ryosuke UsuiDivision of Nephrology, Department of Medicine, Yachiyo Medical Center, Tokyo Women's Medical University, 477-96, Yachiyo, Chiba, Japan. fzk11643@nifty.com.
Masaki TakahashiDivision of Nephrology, Minami-Senju Hospital, Tokyo, Japan.
Kosaku NittaDepartment of Medicine IV, Tokyo Women's Medical University, Tokyo, Japan.
Minako KoikeDivision of Nephrology, Department of Medicine, Yachiyo Medical Center, Tokyo Women's Medical University, 477-96, Yachiyo, Chiba, Japan.
Tokyo Women's Medical University · JPSenju Pharmaceutical (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 34-year-old Japanese male with lipoprotein glomerulopathy (LPG). Renal biopsy showed LPG, and followed by a genetic analysis revealed a mutation in apolipoprotein E gene (APOE Kyoto; Arg25Cys). We started treatment with probucol, bezafibrate, losartan, and allopurinol. Urinary protein decreased in response to treatment but has remained at about 1.27 ± 0.71 g/gCr, and a repeat biopsy which was performed 1 year after the first biopsy showed no clear evidence of pathological remission and complication of other glomerular disease. After 5 years of follow-up after the start of treatment, renal function has almost maintained without apparent deterioration. Interestingly, the course of the urinary protein level closely paralleled his triglyceride and cholesterol levels in a long-term. This observation suggests the importance of tight control of lipid profiles as a means of renoprotection in LPG patient.

Indexed as

APOE KyotoLipoprotein glomerulopathyNephrotic syndrome

Identifiers

PMID28508969
PMCPMC5411641
OpenAlexW2291946547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.